Loading stock data…
INGN
$6.74+0.12 (+1.74%)
Market OpenUpdated 9:51 AM EDT
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inogen, Inc. in the Healthcare sector is trading at $6.62. The stock is currently 27% below its 52-week high of $9.13, remaining 6.0% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why INGN maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.74
Potential Upside
5%
Whystock Fair Value$7.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen thera...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$193.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.55%
Volume
Today's trading volume
25,242
Recent News
How The Inogen (INGN) Story Is Shifting With New Targets And Execution Questions
The latest analyst update trims Inogen’s fair value estimate from $13.00 to about $12.67 per share, a reduction of roughly 2.6%. Analysts are using this adjustment alongside the recent bullish initiation to refresh their models, weigh execution risks, and reassess how comfortable they are with the stock at current levels. As you read on, you will see how these shifting targets shape the evolving narrative around Inogen and what to watch next. Stay updated as the Fair Value for Inogen shifts...
INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves
Inogen posts higher Q1 revenues and improved gross margin as international portable oxygen demand offsets weaker U.S. sales.
Inogen, Inc. Q1 2026 Earnings Call Summary
Moby summary of Inogen, Inc.'s Q1 2026 earnings call
Inogen Q1 Earnings Call Highlights
Inogen (NASDAQ:INGN) reported first-quarter 2026 revenue of $85.1 million, up 3.4% year over year and “ahead of our expectations,” President and CEO Kevin Smith said on the company’s earnings call. Management pointed to continued strength internationally, partially offset by ongoing pressure in U.S.
Inogen (INGN) Reports Q1 Loss, Beats Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of -25.00% and +3.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?